2017 Expert Consensus Decision Pathway on Role of Non-Statin Therapies for LDL Cholesterol - Public Comment Survey

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Public Comment Period
May 12 - May 26, 2017



We invite you to review the draft 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

This focused update incorporates new clinical trial data, released at ACC’s scientific session in March 2017, on long-term cardiovascular outcomes of PCSK9 inhibitors. As with the original 2016 document, the goal is to provide practical guidance for clinicians and patients in situations not covered by the 2013 ACC/AHA cholesterol guideline.

The updated text is clearly marked. Please provide comments on the updated and new text ONLY.

This draft will be edited based on comments received during the public comment period. The final draft will be submitted to the ACC for approval and will be published in the Journal of the American College of Cardiology.

Please enter the information below and then click the "Submit" button.  A new page will appear which will contain links to the Public Comment Draft and Public Comment Response Form.  Please click on the links to access the documents. 

Please email your completed Public Comment Response Form to pathwaycomment@acc.org. 

Questions?  Please contact pathwaycomment@acc.org.

Thank you for participating in this public comment process.

Please complete the following information:  (answer required)

Current Practice Setting (select all that apply): 



 

Years in Practice:




Type of Practitioner:





 

Areas of Specialty (select all that apply):